Chembio Diagnostics (CEMI) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Chembio Diagnostics Reports Third Quarter 2016 Financial Results
November 10, 2016 8:50 AM ESTMEDFORD, N.Y., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today reported financial results for the three and nine months ended September 30, 2016.
John J. Sperzel III, Chief Executive Officer, stated, The Company made important advances in multiple areas during the third quarter of 2016, intended to prepare the Company for growth: commercialization, regulatory approvals, product development grants, and equity financing. With respect to Chembio's commercial infrastructure, the Company appointed two seasoned executives to build our worldwide sales and marketing... More
